Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.54 |
| ▸ | CNR2 | P34972 | 4/20 | 0.54 |
| ▸ | ACHE | P22303 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27821228 | 0.77 | CNR2 (0.64) | CNR1CNR2ACHEKDM4EGUCY1B2 | |
| SCHEMBL13991168 | 0.76 | PTGS2 (0.42) | KEAP1NFE2L2PTGS2TP53MAPT | |
| SCHEMBL2760339 | 0.75 | CNR2 (0.70) | CNR1CNR2ACHEKDM4EGUCY1B2 | |
| SCHEMBL12092607 | 0.72 | CNR2 (0.76) | CNR1CNR2ACHEKDM4EGUCY1B2 | |
| SCHEMBL10829748 | 0.72 | CNR1 (0.62) | CNR1CNR2ACHEKDM4EGUCY1B2 | |
| SCHEMBL13618343 | 0.71 | F2RL3 (0.66) | CNR1CNR2ACHEKDM4ECYP1A2 | |
| SCHEMBL27520009 | 0.71 | CNR1 (0.65) | CNR1CNR2ACHEKDM4EGUCY1B2 | |
| SCHEMBL2739310 | 0.71 | CNR2 (0.65) | CNR1CNR2ACHEKDM4EGUCY1B2 | |
| SCHEMBL13924082 | 0.71 | ALDH1A1 (0.40) | PTGS2TP53MAPTSMN1; SMN2 | |
| SCHEMBL17508607 | 0.71 | CNR1 (0.48) | CNR1CNR2ACHEKDM4EGUCY1B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2173716-B1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH HETEROARYL TOSYLATES AND HETEROARYL BENZENESULFONATES | SANOFI SA (FR) | 2014-03-19 | — | — | EP | disclosed |
| US-8420812-B2 | Process for the palladium-catalyzed coupling of terminal alkynes with heteroaryl tosylates and heteroaryl benzenesulfonates | SANOFI (FR) | 2013-04-16 | — | — | US | disclosed |
| US-20100261900-A1 | Process for the palladium-catalyzed coupling of terminal alkynes with heteroaryl tosylates and heteroaryl benzenesulfonates | SANOFI-AVENTIS (FR) | 2010-10-14 | — | — | US | disclosed |
| EP-2173716-A1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH HETEROARYL TOSYLATES AND HETEROARYL BENZENESULFONATES | Sanofi-Aventis (FR) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009003590-A1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH HETEROARYL TOSYLATES AND HETEROARYL BENZENESULFONATES | SANOFI-AVENTIS (FR) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261900-A1 | Process for the palladium-catalyzed coupling of terminal alkynes with heteroaryl tosylates and heteroaryl benzenesulfonates | DDT, TYR, DDC | CNR1 1297/4885CNR2 1323/4885ACHE 3018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.